Caladrius Biosciences gains on starting kidney disease therapy trial

Lisata Therapeutics

12/04/2022 13:32

** Drug developer's  CLBS.O  shares rise 7% to $0.75
premarket
    ** CLBS says the first patient has been treated in an
early-stage study of its experimental cell therapy, CLBS201, for
the treatment of a kidney-related complication of diabetes
 urn:newsml:reuters.com:*:nGNXb83xFD
    ** The therapy is intended to reverse or slow the decline of
kidney function in diabetic patients with rapidly progressive
chronic kidney disease
    ** Co expects to report top-line data by the first quarter
of 2023
    ** Stock down 17.4% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))